Das A K, Walther P J, Buckley N J, Poulton S H
Department of Surgery, Durham Veterans Administration Medical Center, NC.
Arch Surg. 1989 Jan;124(1):107-10. doi: 10.1001/archsurg.1989.01410010117023.
Although studies done in tissue culture (in vitro) have shown synergism between recombinant human tumor necrosis factor (rhTNF) and chemotherapeutic agents, whether such synergism exists in a complex in vivo environment with acceptable toxic side effects has not been determined, to our knowledge. The effect of rhTNF alone and in combination with cisplatin, etoposide, doxorubicin, or dactinomycin on the growth of heterotransplants of human bladder transitional cell carcinoma was studied using a modified subrenal capsule assay in athymic nude mice. Only etoposide potentiated rhTNF cytotoxicity; no increase in host toxicity was noted. Variably enhanced toxic side effects were seen with other combinations. It is concluded that rhTNF combined with etoposide may have potential clinically exploitable therapeutic "synergism" in the treatment of advanced bladder cancer.
尽管在组织培养（体外）中进行的研究已表明重组人肿瘤坏死因子（rhTNF）与化疗药物之间存在协同作用，但据我们所知，在具有可接受毒性副作用的复杂体内环境中是否存在这种协同作用尚未确定。使用改良的肾包膜下接种法在无胸腺裸鼠中研究了rhTNF单独以及与顺铂、依托泊苷、多柔比星或放线菌素联合使用对人膀胱移行细胞癌异种移植瘤生长的影响。只有依托泊苷增强了rhTNF的细胞毒性；未观察到宿主毒性增加。其他组合则出现了不同程度增强的毒性副作用。结论是，rhTNF与依托泊苷联合使用在晚期膀胱癌治疗中可能具有潜在的临床可利用治疗“协同作用”。
